# A Study Evaluating the Impact of P-tau217 Blood Biomarker Testing on Early Evaluation and Management of Patients Presenting With Cognitive Complaint

> **NCT07140744** · NA · RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 7000 (estimated)

## Conditions studied

- Subjective Cognitive Impairment

## Interventions

- **DIAGNOSTIC_TEST:** P-tau217
- **OTHER:** Standard of Care

## Key facts

- **NCT ID:** NCT07140744
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-22
- **Primary completion:** 2027-10
- **Final completion:** 2027-10
- **Target enrollment:** 7000 (ESTIMATED)
- **Last updated:** 2025-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07140744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07140744, "A Study Evaluating the Impact of P-tau217 Blood Biomarker Testing on Early Evaluation and Management of Patients Presenting With Cognitive Complaint". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07140744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*